Skip to main content

ERRATUM article

Front. Pharmacol., 20 October 2022
Sec. Pharmacology of Anti-Cancer Drugs
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1058178

Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma

This article is an erratum on:

  1. Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma

    1. Read original article
Frontiers Production Office Frontiers Production Office*

An Erratum on
Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung a denocarcinoma

by Teng, J., Zhou, K., Lv, D., Wu, C., and Feng, H. (2022). Front. Pharmacol. 13:714408. doi: 10.3389/fphar.2022.714408

Due to a production error, the author affiliations were listed incorrectly, as “Junjie Teng1,2,†, Kai Zhou2,†, Dongxiao Lv2, Changshun Wu3,* and Hong Feng2,*” instead of “Junjie Teng1,2,†, Kai Zhou1,†, Dongxiao Lv1, Changshun Wu3,* and Hong Feng1,*”.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: ErbB2 mutation, afatinib, adenocarcinoma cell lung carcinoma, PTEN mutation, immunotherapy

Citation: (2022) Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma. Front. Pharmacol. 13:1058178. doi: 10.3389/fphar.2022.1058178

Received: 30 September 2022; Accepted: 30 September 2022;
Published: 20 October 2022.

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.